Huons Co., Ltd.

Equities

A243070

KR7243070000

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
33,850 ^KRW	0.00%		-3.15%	-11.85%

27/03	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI
20/03	Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor

June 11, 2021

On June 11, 2021, PanGen Biotech Inc. (KOSDAQ:A222110) closed the transaction.

Latest news about Huons Co., Ltd.

PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	27/03	CI
Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	18/03	CI
GenEdit Inc. announced that it has received $24 million in funding from Korea Innovative Medicines Consortium, Dong-A ST Co., Ltd., Huons Co., Ltd.	24/01	CI
Huons Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
South Korea's Huons to Export Anesthetics to Canada	01/23/01	MT
GenEdit Inc. amended terms of the transaction	28/23/28	CI
South Korean Stocks Turn Upbeat as China COVID-19 Lockdown Restrictions Ease; Huons Adds 1%	29/22/29	MT
Huons to Invest $18.3 Million to Raise Production Capacity for Injectable Products at Jecheon Plant	29/22/29	MT
GenEdit Inc. announced that it expects to receive $30 million in funding	09/22/09	CI
Haemato : to Seek EU Approval for Botox Product	25/21/25	MT
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor	11/21/11	CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor	03/21/03	CI
Pharmcadd Co, Ltd announced that it has received $16 million in funding from a group of investors	19/21/19	CI
Master Meditech Inc. announced that it has received KRW 8 billion in funding from Samho Green Investment, Inc., Paratus Investment Inc., Spring Camp, Huons Co., Ltd., Pharmbio Co., Ltd., INNOCENCE Co.Ltd	29/21/29	CI
Tranche Update on Huons Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	23/21/23	CI
Tranche Update on Huons Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	23/21/23	CI
Huons Co., Ltd.'s Equity Buyback announced on August 14, 2020, has expired with 80,102 shares, representing 0.74% for KRW 4,989.56 million.	18/21/18	CI
LIPAC Oncology Announces Major Partnering Milestone Achieved in Its License Agreement with Huons Co., Ltd	10/20/10	CI
Tranche Update on Huons Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	23/20/23	CI
Huons Co., Ltd. announced that it has received KRW 50 billion in funding from a group of investors	13/20/13	CI
Huons Co., Ltd. announced that it expects to receive KRW 50 billion in funding from a group of investors	11/20/11	CI
Huons Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	14/20/14	CI
Huons Co., Ltd. authorizes a Buyback Plan.	14/20/14	CI
LIPAC Oncology and Huons Co. Announces Exclusive Licensing Agreement for TSD-001 in Korea	16/19/16	CI

Chart Huons Co., Ltd.

Duration

Period

More charts

Company Profile

Huons Co., Ltd. is a Korea-based company principally engaged in manufacture of general medicine and special medicine.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Huons Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

33,850 KRW

Average target price

54,000 KRW

Spread / Average Target

+59.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUONS CO., LTD.	-11.85%	295M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.76%	364B
MERCK & CO., INC.	+20.59%	326B
ABBVIE INC.	+5.64%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+11.02%	167B
PFIZER, INC.	+0.09%	161B

Other Pharmaceuticals